Oligodendroglioma - Pipeline Insight, 2024

Oligodendroglioma - Pipeline Insight, 2024

DelveInsight’s, “Oligodendroglioma - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Oligodendroglioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Oligodendroglioma Understanding

Oligodendroglioma: Overview

Oligodendroglioma (OG) is a type of diffusely infiltrating glioma and constitutes approximately 5% of primary intracranial tumors. Oligodendroglial tumors can be divided into two groups based on the classification of the world health organization (WHO): grade II oligodendroglioma and grade III (anaplastic) oligodendroglioma. Most commonly occurring between 25 and 45 years of age, grade III oligodendrogliomas tend to present 10 years later than grade II tumors and can rarely develop in younger and older populations. Oligodendroglioma is genetically defined as a tumor confirmed to harbor either an IDH1 or IDH2 mutation along with co-deletion of chromosome arms 1p and 19q.

OGs are found predominantly in the cerebral hemisphere white matter (80 to 90% supratentorial), most commonly in the frontal lobes, but temporal and parietal lobe involvement is not uncommon. Treatment of OG is multifactorial, consisting of surgical, chemotherapy, and radiation therapy treatment methods.

Surgical treatments are approached on a case-by-case basis. Radiation oncology with radiotherapy (RT) also plays an important role in the treatment of OG, most often after surgical resection. Standard focal or limited field hyperfractionated RT is typically employed. The field consists of the resection bed, area of residual enhancement on T1 post-contrast imaging, and a margin of up to 3 cm, including the adjacent T2/FLAIR hyperintensity that may represent infiltrating disease.

""Oligodendroglioma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oligodendroglioma pipeline landscape is provided which includes the disease overview and Oligodendroglioma treatment guidelines. The assessment part of the report embraces, in depth Oligodendroglioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oligodendroglioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Oligodendroglioma. The therapies under development are focused on novel approaches to treat/improve Oligodendroglioma.
• In July 2021, Oblato announced that it received an agreement from the FDA for its plan to submit an intermediate size expanded access protocol for use of OKN-007 in patients with high-grade gliomas.
• In January 2021, Chimerix acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, in clinical testing to selectively induce cell death in multiple cancer types.
• In October 2018, Oblato acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of glioblastoma, a deadly form of brain cancer.
• EpicentRx in collaboration with the Texas Children's Cancer Center in Houston, imitated the start of a Phase 1 study to examine the safety and benefit of its lead small molecule, RRx-001, plus irinotecan and temozolomide for pediatric patients with recurrent or progressive malignant solid and central nervous system tumors. The study, PIRATE (NCT04525014) was conceived and developed by doctors Holly Lindsay and Patricia Baxter at the Texas Children's Cancer Center and will enroll patients 1 to 21 years of age with recurrent or progressive malignant primary brain or spinal cord tumors and solid tumors, excluding lymphomas.

This segment of the Oligodendroglioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Oligodendroglioma Emerging Drugs

• ONC201: Chimerix

ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation. Recurrent glioma is a form of brain cancer with a particularly poor prognosis having a median overall survival of approximately eight months. Recurrent pediatric patients, with cancer that carries the H3 K27M mutation, have an even worse prognosis with median overall survival of approximately four months. Compelling responses at this stage of disease are rare and lack durability. Patients with this mutation are considered grade IV by the World Health Organization, regardless of underlying histology or age.

• RRx-001: EpicentRx

RRx-001 is a lead small molecule, immunotherapy targeting the CD47 – SIRPα axis and has been evaluated in multiple clinical studies. The genesis for the PIRATE trial was based on several preceding clinical trials which have established potential evidence that RRx-001 increases chemotherapy delivery and uptake in tumors. A Phase 1 clinical trial called G-FORCE (NCT02871843) and a Phase 1/2 clinical trial called BRAINSTORM (NCT02215512) demonstrated the safety of RRx-001 as well as potential evidence of clinical benefit in adult patients with glioblastoma or GBM and with brain metastases, respectively.

Further product details are provided in the report……..

Oligodendroglioma: Therapeutic Assessment

This segment of the report provides insights about the Oligodendroglioma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Oligodendroglioma

There are approx. 10+ key companies which are developing the therapies Oligodendroglioma. The companies which have their Oligodendroglioma drug candidates in the most advanced stage, i.e. Phase II include, Pfizer.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Oligodendroglioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Gene Therapy
• Small molecule
• Antibody
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Oligodendroglioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Oligodendroglioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oligodendroglioma drugs.

Oligodendroglioma Report Insights

• Oligodendroglioma Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Oligodendroglioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Oligodendroglioma drugs?
• How many Oligodendroglioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oligodendroglioma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oligodendroglioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oligodendroglioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• EpicentRx
• Pfizer
• Oblato
• Istari Oncology
• Bayer
• Chimerix
• Pfizer
• Abbott

Key Products

• RRx-001
• PD0332991
• Disufenton
• Lerapolturev
• Sorafenib
• ONC-206
• Temsirolimus
• Everolimus